During this two day conference, you will become acquainted with examples and strategies to develop, transfer and manufacture Vaccines and Biologics. Experts from authorities and industry will give you an insight view in their experience with optimising development processes, regulatory requirements and possible pitfalls.
The site visit at IDT’s new manufacturing site will close the gap between theoretical background and practical implementation.
Additionally you will get information about the current developments on microbiological safety for biopharmaceutical products.
The way from product development to manufacturing of Biopharmaceuticals, Biosimilars and Biologics is complex, time-consuming and risky. The product development business is expected to provide long-term revenues, which could be significant for blockbusters on the market, even for Biopharmaceuticals. Even Especially the pharmaceutical industry’s strategy to retreat operationally from this market segment should encourage small and mid-sized biopharmaceutical companies to look for convincing and profitable product candidates. Furthermore, this development provides contract manufacturers with good prospects for developing and manufacturing biological products.
The time aspect should not be underestimated - 8-12 years from the beginning to product launch is a general rule.